Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis

Veterinary Parasitology

Volumn 212, Issue 3-4, 2015, Pages 130-139

  Shahbazi, Mehdi ^a,b   Zahedifard, Farnaz ^b   Saljoughian, Noushin ^b   Doroud, Delaram ^b   Jamshidi, Shahram ^c   Mahdavi, Niousha ^c   Shirian, Sadegh ^d   Daneshbod, Yahya ^d   Hamid Zarkesh Esfahani, Sayyed ^a   Papadopoulou, Barbara ^e   Rafati, Sima ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d Dr Daneshbod Pathology Laboratory Tehran   (Iran)

^e University Laval   (Canada)

Author keywords

Canine leishmaniasis; Delivery systems; Immune response; Vaccine

Indexed keywords

CYSTEINE PROTEINASE; CYSTEINE PROTEINASE TYPE I; CYSTEINE PROTEINASE TYPE II; DNA VACCINE; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NANOPARTICLE; PROTOZOAL VACCINE; PROTOZOON ANTIBODY;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA IMMUNIZATION; DOG; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; ELECTROPORATION; FEMALE; FUSION GENE; GFP GENE; HYPERSENSITIVITY; IMMUNOGLOBULIN BLOOD LEVEL; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS; MALE; NONHUMAN; PARASITE LOAD; PROTEIN BLOOD LEVEL; ANIMAL; BLOOD; CONTROLLED CLINICAL TRIAL; DOG DISEASES; IMMUNIZATION; IMMUNOLOGY; LEISHMANIASIS, VISCERAL; PARASITOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VETERINARY;

ANIMALS; ANTIBODIES, PROTOZOAN; DOG DISEASES; DOGS; ELECTROPORATION; FEMALE; IMMUNIZATION; LEISHMANIASIS, VISCERAL; MALE; NANOPARTICLES; PROTOZOAN VACCINES; REAL-TIME POLYMERASE CHAIN REACTION; VACCINES, DNA;

EID: 84942982898     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2015.07.005     Document Type: Article

References (63)

1. Alvar J., Aparicio P., Aseffa A., Den Boer M., Canavate C., Dedet J.-P., Gradoni L., Ter Horst R., López-Vélez R., Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 2008, 21:334-359.
2. Barbieri C. Immunology of canine leishmaniasis. Parasite Immunol. 2006, 28:329-337.
3. Becker S., Kuznetsov A. Local temperature rises influence in vivo electroporation pore development: a numerical stratum corneum lipid phase transition model. J. Biomech. Eng. 2007, 129:712-721.
4. Bergeron L.M., McCandless E.E., Dunham S., Dunkle B., Zhu Y., Shelly J., Lightle S., Gonzales A., Bainbridge G. Comparative functional characterization of canine IgG subclasses. Vet. Immunol. Immunopathol. 2014, 157:31-41.
5. Binhazim A.A., Chapman W.L., Latimer K.S., Styles M., Comer K. Canine leishmaniasis caused by Leishmania leishmania infantum in two Labrador retrievers. J. Vet. Diagn. Invest. 1992, 4:299-305.
6. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza E., Hashimoto Okada L.Y., de A Trivellato F.A., Kawasaki J.K.A., Costa A.C., Reis A.B., Genaro O., Batista L.M.M. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004, 22:2234-2243.
7. Carrillo E., Ahmed S., Goldsmith-Pestana K., Nieto J., Osorio Y., Travi B., Moreno J., McMahon-Pratt D. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine 2007, 25:1534-1543.
8. Chamizo C., Moreno J., Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet. Immunol. Immunopathol. 2005, 103:67-75.
9. Charest H., Matlashewski G. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol. Cell. Biol. 1994, 14:2975-2984.
10. Coelho E.A.F., Tavares C.A.P., Carvalho F.A.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., Charest H., Matlashewski G., Gazzinelli R.T., Fernandes A.P. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect. Immun. 2003, 71:3988-3994.
11. Coler R.N., Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol. 2005, 21:244-249.
12. Cukjati D., Batiuskaite D., André F., Miklavčič D., Mir L.M. Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry 2007, 70:501-507.
13. Day M. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet. Parasitol. 2007, 147:2-8.
14. Deplazes P., Smith N., Arnold P., Lutz H., Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol. 1995, 17:451-458.
15. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27:305-318.
16. Desjeux P., Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol. 2003, 97:3-15.
17. Doroud D., Vatanara A., Zahedifard F., Gholami E., Vahabpour R., Najafabadi A.R., Rafati S. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J. Pharm. Pharm. Sci. 2010, 13:320-335.
18. Doroud D., Zahedifard F., Vatanara A., Najafabadi A.R., Taslimi Y., Vahabpour R., Torkashvand F., Vaziri B., Rafati S. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J. Control. Release 2011, 153:154-162.
19. Doroud D., Zahedifard F., Vatanara A., Taslimi Y., Vahabpour R., Torkashvand F., Vaziri B., Najafabadi A.R., Rafati S. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl. Trop. Dis. 2011, 5:e1236.
20. Escors D., Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. 2010, 58:107-119.
21. Fernandes A.P., Costa M.M.S., Coelho E.A.F., Michalick M.S.M., de Freitas E., Melo M.N., Luiz Tafuri W., Resende D.d.M., Hermont V., Abrantes C.d.F. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008, 26:5888-5895.
22. Fujiwara R.T., Vale A.M., da Silva J.C.F., da Costa R.T., da Silva Quetz J., Martins Filho O.A., Reis A.B., Oliveira R.C., Machado-Coelho G.L., Bueno L.L. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet. Res. 2005, 36:827-838.
23. Gautam S., Kumar R., Maurya R., Nylén S., Ansari N., Rai M., Sundar S., Sacks D. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J. Infect. Dis. 2011, 204:1134-1137.
24. Ghosh A., Labrecque S., Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001, 19:3169-3178.
25. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 2000, 18:927-974.
26. Hoerauf A., Solbach W., Lohoff M., Röllinghoff M. The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice. Int. Immunol. 1994, 6:1117-1124.
27. Iniesta L., Gállego M., Portús M. Immunoglobulin G and E responses in various stages of canine leishmaniosis. Vet. Immunol. Immunopathol. 2005, 103:77-81.
28. Joshi M.D., Müller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71:161-172.
29. Khalil E., Hassan A., Zijlstra E., Mukhtar M., Ghalib H., Musa B., Ibrahim M., Kamil A.A., Elsheikh M., Babiker A. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356:1565-1569.
30. Lachaud L., Marchergui-Hammami S., Chabbert E., Dereure J., Dedet J.P., Bastien P. Comparison of six PCR methods using peripheral blood for detection of canine visceral leishmaniasis. J. Clin. Microbiol. 2002, 40:210-215.
31. Lage R.S., Oliveira G.C., Busek d., Guerra S., Giunchetti L.L., Correa-Oliveira R.C., Reis R.A.B. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet. Immunol. Immunopathol. 2007, 115:135-145.
32. Leandro C., Santos-Gomes G., Campino L., Romao P., Cortes S., Rolao N., Gomes-Pereira S., Rica Capela M., Abranches P. Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis. Vet. Immunol. Immunopathol. 2001, 79:273-284.
33. Lemesre J.-L., Holzmuller P., Cavaleyra M., Gonçalves R.B., Hottin G., Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005, 23:2825-2840.
34. Manna L., Reale S., Viola E., Vitale F., Manzillo V.F., Michele P.L., Caracappa S., Gravino A.E. Leishmania DNA load and cytokine expression levels in asymptomatic naturally infected dogs. Vet. Parasitol. 2006, 142:271-280.
35. Mauricio I., Stothard J., Miles M. The strange case of Leishmania chagasi. Parasitol. Today 2000, 16:188-189.
36. Mizbani A., Taheri T., Zahedifard F., Taslimi Y., Azizi H., Azadmanesh K., Papadopoulou B., Rafati S. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 2009, 28:53-62.
37. McDowell M.A., Rafati S. Neglected tropical diseases-Middle East and North Africa. Visceral Leishmaniasis: Immune Mechanisms and Insight in Vaccine Development and Control 2014, 141-171. Springer Verlag, Wein. S.A. Ejazi, N. Ali (Eds.).
38. Molano I., Alonso M.G., Miron C., Redondo E., Requena J., Soto M., Nieto C.G., Alonso C. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 2003, 92:1-13.
39. Momo C., Jacintho A.P.P., Moreira P.R.R., Munari D.P., Machado G.F., Vasconcelos R.d.O. Morphological changes in the bone marrow of the dogs with visceral Leishmaniasis. Vet. Med. Int. 2014.
40. Moreno J., Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol. 2002, 18:399-405.
41. Oryan A., Shirian S., Tabandeh M.-R., Hatam G.-R., Randau G., Daneshbod Y. Genetic diversity of Leishmania major strains isolated from different clinical forms of cutaneous leishmaniasis in southern Iran based on minicircle kDNA. Infect. Genet. Evol. 2013, 19:226-231.
42. Pinelli E., Gonzalo R.M., Boog C.J., Rutten V.P., Gebhard D., Del Real G., Ruitenberg E.J. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur. J. Immunol. 1995, 25:1594-1600.
43. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernadina W., Del Real G., Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect. Immun. 1994, 62:229-235.
44. Ploemen I., Behet M., Nganou-Makamdop K., van Gemert G.-J., Bijker E., Hermsen C., Sauerwein R. Evaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites. Malar. J. 2011, 10. 10.1186.
45. Rafati S., Nakhaee A., Taheri T., Ghashghaii A., Salmanian A.-H., Jimenez M., Mohebali M., Masina S., Fasel N. Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Exp. Parasitol. 2003, 103:143-151.
46. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., Sanos S., Kaye P., Taghikhani M., Jamshidi S. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005, 23:3716-3725.
47. Rafati S., Zahedifard F., Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006, 24:2169-2175.
48. Reis A.B., Teixeira-Carvalho A., Vale A.M., Marques M.J., Giunchetti R.C., Mayrink W., Guerra L.L., Andrade R.A., Corrêa-Oliveira R., Martins-Filho O.A. Isotype patterns of immunoglobulins: Hallmarks for clinical status and tissue parasite density in brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 2006, 112:102-116.
49. Reithinger R., Davies C.R. Canine leishmaniasis: novel strategies for control. Trends Parasitol. 2002, 18:289-290.
50. Resende D.M., Caetano B.C., Dutra M.S., Penido M.L., Abrantes C.F., Verly R.M., Resende J.M., Piló-Veloso D., Rezende S.A., Bruna-Romero O. Epitope mapping and protective immunity elicited by adenovirus expressing theLeishmania amastigote specific A2 antigen: correlation with IFN-γ and cytolytic activity by CD8+ T cells. Vaccine 2008, 26:4585-4593.
51. Saljoughian N., Zahedifard F., Doroud D., Doustdari F., Vasei M., Papadopoulou B., Rafati S. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Parasite Immunol. 2013, 35:397.
52. ® vaccine. Vaccine 2007, 25:6176-6190.
53. Shidhaye S., Vaidya R., Sutar S., Patwardhan A., Kadam V. Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr. Drug Deliv. 2008, 5:324-331.
54. Shirian S., Oryan A., Hatam G.-R., Panahi S., Daneshbod Y. Comparison of conventional, molecular, and immunohistochemical methods in diagnosis of typical and atypical cutaneous Leishmaniasis. Arch. Pathol. Lab. Med. 2014, 138:235-240.
55. Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M., Ferrer L., Bourdeau P., Oliva G., Baneth G. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet. Parasitol. 2009, 165:1-18.
56. Solano-Gallego L., Miró G., Koutinas A., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G. LeishVet guidelines for the practical management of canine leishmaniosis. Parasites Vectors 2011, 4:86.
57. Solano-Gallego L., Riera C., Roura X., Iniesta L., Gallego M., Valladares J.E., Fisa R., Castillejo S., Alberola J., Ferrer L. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas: evolution in the course of infection and after treatment. Vet. Parasitol. 2001, 96:265-276.
58. Stober C.B., Lange U.G., Roberts M.T., Alcami A., Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J. Immunol. 2005, 175:2517-2524.
59. Trollet C., Bloquel C., Scherman D., Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr. Gene Ther. 2006, 6:561-578.
60. Wissing S., Kayser O., Müller R. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
61. World Health Organization Manual on Visceral Leishmaniasis Control 1996, http://apps.who.int/iris/handle/10665/63637.
62. Zanin F.H., Coelho E.A., Tavares C.A., Marques-da-Silva E.A., Silva Costa M.M., Rezende S.A., Gazzinelli R.T., Fernandes A.P. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect. 2007, 9:1070-1077.
63. Zhang W.W., Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol. 2001, 39:935-948.